Lomitapide, a cholesterol-lowering drug, is an anticancer agent that induces autophagic cell death via inhibiting mTOR
Abstract Autophagy is a biological process that maintains cellular homeostasis and regulates the internal cellular environment. Hyperactivating autophagy to trigger cell death has been a suggested therapeutic strategy for cancer treatment. Mechanistic target of rapamycin (mTOR) is a crucial protein...
Main Authors: | Boah Lee, Seung Ju Park, Seulgi Lee, Jinwook Lee, Eunbeol Lee, Eun-Seon Yoo, Won-Suk Chung, Jong-Woo Sohn, Byung-Chul Oh, Seyun Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2022-07-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-022-05039-6 |
Similar Items
-
Lomitapide en hipercolesterolemia familiar heterocigota
by: Juan Esteban Bedoya Loaiza, et al.
Published: (2022-02-01) -
Efficacy of Long-Term Treatment of Autosomal Recessive Hypercholesterolemia With Lomitapide: A Subanalysis of the Pan-European Lomitapide Study
by: Laura D’Erasmo, et al.
Published: (2022-08-01) -
Increased mTOR Signaling and Impaired Autophagic Flux Are Hallmarks of SARS-CoV-2 Infection
by: Érika Pereira Zambalde, et al.
Published: (2022-12-01) -
Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition
by: Marco Cordani, et al.
Published: (2016-08-01) -
Lomitapide repurposing for treatment of malignancies: A promising direction
by: Hua-Tao Wu, et al.
Published: (2024-06-01)